- About this Journal ·
- Abstracting and Indexing ·
- Aims and Scope ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
Journal of Transplantation
Volume 2011 (2011), Article ID 252387, 12 pages
Human Liver Cells Expressing Albumin and Mesenchymal Characteristics Give Rise to Insulin-Producing Cells
1Sheba Regenerative Medicine, Stem cells and Tissue engineering Center, Sheba Medical Center, Tel-Hashomer 52621, Israel
2Diabetes Research Institute, University of Miami Leonard M. Miller School of Medicine, 1450 NW 10th Avenue, Miami, FL 33136, USA
3Department of Human Genetics and Molecular Medicine, Sackler School of Medicine, Tel-Aviv University, 69978 Tel-Aviv, Israel
4Obstetrics and Gynecology Department, Sapir Medical Ctrter 44281 Kfar Saba, Israel
5The Institute for Pathology, Sheba Medical Center, 52621 Tel-Hashomer, Israel
6Biotechnology and Biotherapy Group, Centre de Recherche, Institut du Cerveau et de la Moelle CNRS UMR7225, INSERM UMRS795, Université Pierre et Marie Curie, 75005 Paris, France
7The Miami Transplant Institute, University of Miami Leonard M. Miller School of Medicine, 1450 NW 10th Avenue, Miami, FL 33136, USA
8Rabin Medical Center, Beilinson Campus, 49100 Petah-Tiqva, Israel
Received 28 April 2011; Accepted 5 June 2011
Academic Editor: Thierry Berney
Copyright © 2011 Irit Meivar-Levy et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Activation of the pancreatic lineage in the liver has been suggested as a potential autologous cell replacement therapy for diabetic patients. Transcription factors-induced liver-to-pancreas reprogramming has been demonstrated in numerous species both in vivo and in vitro. However, human-derived liver cells capable of acquiring the alternate pancreatic repertoire have never been characterized. It is yet unknown whether hepatic-like stem cells or rather adult liver cells give rise to insulin-producing cells. Using an in vitro experimental system, we demonstrate that proliferating adherent human liver cells acquire mesenchymal-like characteristics and a considerable level of cellular plasticity. However, using a lineage-tracing approach, we demonstrate that insulin-producing cells are primarily generated in cells enriched for adult hepatic markers that coexpress both albumin and mesenchymal markers. Taken together, our data suggest that adult human hepatic tissue retains a substantial level of developmental plasticity, which could be exploited in regenerative medicine approaches.
A cure for type 1 diabetes mellitus depends on replenishing functional insulin-producing cells. However, the limited supply of pancreatic islets from cadaver donors and the need for life-long immune suppression makes pancreas or pancreatic islet allotransplantation impractical for the vast majority of patients. This hurdle has led to a search for new alternate sources of insulin-producing cells or tissues [1–3]. A challenging approach to generating surrogate β-cells for cell replacement therapy in diabetes is the direct reprogramming of liver cells into insulin-producing cells. Liver and pancreatic cells share a common developmental origin, making liver cells good candidates for manipulation into β-like cells . Both tissues may share a common population of progenitor cells . For example, cells with properties virtually identical to those of hepatic oval cells can also emerge in the pancreas, especially after the ablation of acinar cells . Upon transplantation, these pancreas-derived oval cells can differentiate into functional hepatocytes and bile ducts . The reciprocal conversion of rodent [8–13] and human [14–18] liver cells into pancreatic endocrine cells by transdifferentiation or direct cellular reprogramming has also been described. Liver cells have been induced to differentiate into insulin-producing cells by ectopic expression of pancreatic transcription factors, the best studied of which is PDX-1, a key regulator of pancreatic development and insulin expression in adult pancreatic beta cells [8, 10, 14, 16–19]. However, whether transcription factor-induced reprogramming primarily occurs in “stem-like” pluripotent cells or rather adult cells can directly give rise to committed cells of alternate lineages is questionable and presently analyzed.
Adult liver contains several populations of cells, including hepatocytes, cholangiocytes, endothelial stellate cells, and bone marrow- (BM-) derived cells [20–22]. Activation of the pancreatic lineage in mice in vivo has been reported to occur in several areas of the intact organ [8, 11, 23, 24]. PDX-1-induced insulin production in mouse livers in vivo appears to occur mainly in the parenchyma of the liver around the central veins [8, 11, 25]. On the other hand, NEUROD1 and betacellulin-induced insulin production occurs mainly in cells close to the hepatic capsule . NGN-3 and betacellulin induce the transdetermination of parenchymal hepatocytes and hepatic progenitor cells and possibly endoderm-derived oval cells in periportal areas of the liver .
The aim of the present study was to characterize the human-derived liver cells capable of giving rise to insulin-producing cells and determine whether they originate from mature or hepatic progenitor cells. The definite characteristics of hepatic progenitor cells which populate the adult human organ is controversial; however, there is a wide agreement that all these populations express the epithelial marker, EpCAM [27–29]. We generated in vitro primary cultures of liver cells derived from different human donors that already demonstrated a capacity to reprogram along the endocrine pancreatic and β-cell-like lineages by ectopic expression of pancreatic transcription factors [14–16, 30]. The origin of the induced insulin-positive cells in proliferating cultures of adult human liver cells is not clear, because the original liver cell morphology is altered and the cells undergo massive dedifferentiation, which is further augmented by ectopic PDX-1 expression and the reprogramming process itself . Here, we characterize the cells in the adherent, proliferating cultures derived from adult human liver and demonstrate their mesenchymal-like characteristics. Using a genetic cell lineage tracing for albumin, we demonstrate that the cells coexpress both mesenchymal and adult hepatic markers, but none of the cells express EpCAM. The mesenchymal-like cells that originate from cells expressing albumin give rise to insulin expression upon ectopic PDX-1 expression.
2. Material and Methods
2.1. Human Liver Cells
Adult human liver tissues were obtained from 3 different liver transplantation surgeries from 4–10-years-old children and 8 individuals over forty years old. Liver tissues were used with approval from the Committee on Clinical Investigations (institutional review board).
Isolation of human liver cells was performed as previously described [16, 31]. Briefly, the cells were digested by 0.03% Collagenase type I (Worthington Biochemical Corp., NJ) and cultured in Dulbecco's minimal essential medium (1 gr/L glucose) supplemented with 10% FCS, 100 U/mL penicillin, 100 μg/mL streptomycin and 250 ng/mL amphotericin B (Biological Industries, Israel). The medium was changed daily during the first three days in order to remove nonadherent cells. Ninety percent confluent cultures were split using trypsin-EDTA. The cells were kept at 37°C in a humidified atmosphere of 5% CO2 and 95% air.
2.2. Lentivirus Vector Construction and Virus Production
The pTrip albumin promoter (410) nlsCRE DeltaU3 (ALB-Cre) vector was generated by removing with BamHI and XhoI of the enhanced green fluorescent protein (eGFP) coding region from the pTrip ALB eGFP DeltaU3 vector, which contains a fragment of the rat albumin promoter from −423 to −23 relative to the transcription start site. The resulting linearized plasmid was blunt-ended with DNA polymerase I Klenow fragment. The reading frame A Gateway cassette (Gateway Conversion kit; Invitrogen) was next ligated to the blunt-ended vector according to the manufacturer’s instructions, generating a pTrip ALB rfa-Gateway DeltaU3 destination vector. The nlsCRE fragment was amplified by PCR from a plasmid  provided by Guilan Vodjdani (Hospital de la Pitie′, Salpetriere, Paris) using the forward primer 5′ CACCAGATCTATGCCCAAGAAGA.
AGAGG-3′ and the reverse primer 5′-CTCGAGCTAATCGCCATCTTC-3′, and the resulting PCR product was cloned into the pENTR/D/TOPO plasmid (Invitrogen) to generate an nls-CRE entry clone. Both destination vector and entry clone were used for in vitro recombination using the LR clonase II system (Invitrogen) according to the manufacturer’s instructions. The reporter vector was constructed as previously reported .
Virus particles were produced in 293T cells after pCMVdR8.91 and pMD2.G vectors cotransfection. The culture medium was harvested 36–48 h later.
2.3. Viral Infection
Lentiviruses infection was performed 24 hours after plating; liver cells were washed with PBS and infected with a 1 : 1 mixture of the two viruses at multiplicity of infection (MOI) 3 : 1 in growth media containing 8 ng/mL polybrene overnight. The medium was then replaced with culture medium, and the cells were refed twice a week and split 1 : 3 once a week. The percentiles of eGFP and DsRed2 positive cells were analyzed using a Beckman Coulter FC500 flow cytometer or FACS Calibur, using the CellQuest program.
2.4. Animal Studies
All animals were maintained and animal experiments were carried out under the supervision and guidelines of the Sheba Medical center Institutional Animal Welfare Committee (177/2002).
Cells at passage 4, were harvested, washed twice with sterile PBS, counted, and resuspended in Matrigel (BD Biosciences). Six-week-old female athymic nude mice were injected subcutaneously in both flanks with human liver cells at density of viable cells/100 μL as previously described . Five mice were used in each group. Tumor size was measured with a linear caliper for up to 17 weeks.
2.5. Flow Cytometry
Liver-derived cells were harvested and washed with flow cytometry buffer consisting of 1% BSA and 0.1% sodium azide (Sigma, St. Louis, Mo,USA) in phosphate buffered saline (Invitogen, Carlsbad, Calif,USA). For the cell surface antigen detection, approximately 105 cells labeled with conjugated monoclonal antibodies. Intracellular staining was preformed using Intracellular Staining Flow Assay Kit (Imgenex, San Diego, Calif, USA) following manufacturer’s instruction. Control samples included unstained cells, isotype antibody stained cells, and single fluorochrome-stained cells. The antibodies used in this study are listed in supplemental material data 1.
The cells were analyzed using a Beckman Coulter FC500 flow cytometer or FACS Calibur, using the CellQuest program.
2.6. Cell Sorting
Three weeks after lentiviruses infection the labeled liver-derived cells were sorted using a fluorescence-activated cell sorter (FACS) (Aria cell sorter; Becton Dickinson, San Jose, Calif, USA) with a fluorescein isothiocyanate filter (530/30 nm) for eGFP and a Pe-Texas Red filter (610/20 nm) for DsRed2.
2.7. In Vitro Adipogenic and Osteogenic Differentiation
Following manufacturer’s instructions (Human Mesenchymal Stem Cell Functional Identification Kit, R&D Systems, Minneapolis, Minn,USA), human liver-derived cells at passage 4 were plated on cover slips at 2,000 cells/cm2 in 6-well tissue culture-treated plates in the presence of the adipogenic or osteogenic supplements provided by the company. The appropriate supplemented medium was changed twice per week. After 14 days in culture, the adipogenic culture formed adipogenic-like vacuoles. The plates were fixed with 4% paraformaldehyde for 20 minutes and stained with Oil Red O (Sigma). The osteogenic differentiation cultures were incubated for 21 days and fixed and stained with 1% Alizarin Red solution pH 4.1 (Sigma). The calcium deposits were stained orange-red. Slides were imaged under a Leica DMLB microscope using the Leica Application Suite version 2.7.1 R1 software.
2.8. RNA Isolation, RT and RT-PCR Reactions
Total RNA was isolated, cDNA was prepared and amplified as described previously [8, 16]. Quantitative real-time RT-PCR was performed using ABI StepOnePlus (Applied Biosystems, Calif, USA) as described previously [14, 16, 30]. The primer pairs and annealing temperatures listed in supplemental material data 2.
Human liver cells treated were plated on glass cover slides in six-well culture plates. Forty-eight hours later, the cells were fixed and stained as described previously . The antibodies used in this study are listed in supplemental material data 1.
The slides were analyzed using a fluorescent microscope (Provis, Olympus).
2.10. Statistical Analyses
Statistical analyses were performed using two-sample Students -test assuming unequal variances.
3.1. Characterization of Human Liver-Derived Cells Cultured In Vitro
Adult human liver cells can be propagated in vitro for roughly 20 passages; after an initial 2-week lag, the cells proliferate at a constant rate (Figure 1(a)) [14–17]. In addition to proliferation, a gradual and partial decrease in mature hepatic characteristics is observed . A comparison of the gene expression profiles of primary cultures of adult human liver cells (passages 2–4), and the original intact tissues revealed changes in the repertoire of expressed genes (Figures 1(b) and 1(c)). Human liver-derived cells in culture undergo dedifferentiation, manifested as decreased expression of numerous adult hepatic markers and increased expression of immature and endodermal markers (Figure 1(b)) . Previously, it was reported that hepatic dedifferentiation and downregulation of mature hepatic markers occurs rapidly, within 24 hours in culture . Our data support that as the reduction was detected at any time point analyzed (P0–25 in culture). Despite the massive downregulation of adult hepatic markers, 88 ± 6% of the liver cells in culture maintains albumin expression and production, as demonstrated by flow cytometry and immunofluorescence (Figures 2(a) and 2(b)). Approximately 60% of the cells in culture were positive for another adult hepatic marker α-anti-trypsin (AAT) inhibitor (Figure 2(a)) though at lower levels than in the intact organ . Twenty percent of liver cells in culture express the hepatic fetal marker alpha-fetoprotein (AFP), but none express the hepatic progenitor marker EpCAM or duct cell markers CA19–9 or CK19 [28, 36, 37]. Taken together, these results suggest that the proliferating cells in culture may not represent populations of hepatic stem cells.
Liver cells in culture expressed lower levels of the epithelial marker E-CAD and higher levels of N-CAD compared to intact liver tissues (Figures 1(c) and 2(a)). Such a switch in cadherin expression usually characterizes an epithelial to mesenchymal transition (EMT) process, which also occurs to pancreatic islet cells in culture . In addition to the switch in cadherin expression levels, expression of the transcription factors Snail and Slug was activated, which further strengthens the notion that proliferating human liver cells in culture may undergo an EMT process (Figure 1(c)).
To further uncover the nature and properties of liver-derived cells in in vitro culture, we analyzed the expression of markers that characterize mesenchymal cells. Cellular characterization of the cells in increasing passages indicated that most liver-derived cells in culture express several mesenchymal stem cell (MSC) markers, including CD105, CD90, CD73, and CD29 (Figures 2(a) and 2(c)). Double immunostaining demonstrated the colocalization of hepatic and MSC markers within the same cells (Figure 2(d)). Hematopoietic marker expression was not detected in the human liver-derived cultures (Figure 2(a)). These data suggest that liver-derived cells in culture coexpress hepatic and general MSC markers but may not represent a known hepatic progenitor population, as neither CK-19 nor EpCAM expression is detected [28, 36, 37].
3.2. Developmental Plasticity of Liver-Derived Cells in Culture
The MSC markers present on most liver-derived cells in culture motivated us to analyze whether the cells also exhibit cellular plasticity. Human liver cells at passage 4 were cultured for 21 days under defined differentiation conditions known to activate osteocytes and adipocytes among BM-derived MSCs (Figures 2(e), 2(f), 2(g), and 2(h)). Indeed, human liver cells cultured in adipogenic differentiation medium exhibited lipid-containing droplets visualized by Oil Red staining (Figure 2(e)). Cells cultured in osteogenic differentiation media developed calcium deposits visualized by Alizarin Red staining, which is characteristic of osteogenic differentiation (Figure 2(g)). These data indicate that the liver-derived cells that propagate in vitro acquire developmental plasticity, which may allow them to differentiate along alternate developmental fates in response to applied growth and differentiation conditions. The developmental plasticity these cells exhibited may provide a partial explanation of their capacity to acquire a β-cell phenotype in response to ectopic pancreatic transcription factor expression.
3.3. Liver-Derived Cells Cultured In Vitro Do Not Induce Tumors in Immune Deficient Mice In Vivo
The epithelial-mesenchymal transition in liver has been suggested to be related to invasiveness and metastatic potential in mouse and human cancers [39, 40]. Moreover, BM-derived mesenchymal stem cells have been demonstrated to exhibit tumorigenic capacity upon in vivo implantation [41–43]. Therefore, we analyzed whether the implantation of adult human liver-derived cells potentially generates tumors in vivo upon transplantation in immune-deficient mice. Adult human liver-derived cells at passage 4 were injected subcutaneously into both flanks of nude mice ( cells per injection, 5 mice per group, 2 transplantations per mouse) and tumor growth monitored weekly. Transplantation of tumor-derived cells, such as MDA-MB 231 or Panc-1 cells, resulted in large tumor formation 3–6 weeks after implantation , but none of the mice implanted with liver-derived cells developed visible tumors over 4 months. After 17 weeks, the mice were sacrificed and the area of injection examined. No traces of the cells were identified in the specimens. These data suggest that despite the cellular plasticity manifested earlier, dedifferentiated human liver cells have mesenchymal characteristics but may not carry a risk of uncontrolled cell proliferation or tumor formation.
3.4. Irreversible Tracing of Albumin Expression
The adult human-derived liver cells characterized above were reported in the past to undergo cellular reprogramming and generate insulin-producing cells upon ectopic expression of the pancreatic transcription factor PDX-1 [14, 16, 17, 30]. However, because only a fraction of PDX-1 expressing cells become insulin positive [14, 16], we sought to analyze whether the insulin-producing cells are generated from cells that originally express albumin or a yet unidentified side population of stem-like cells that may be enriched in the hepatic-derived primary cultures. Because PDX-1 turns off the hepatic repertoire of gene expression , we irreversibly tagged albumin expression prior to PDX-1 treatment. Human liver cells at passages 1–3 were coinfected by a dual lentivirus system modified from Russ et al. . This lentivirus system included the CMV-loxP-DsRed2-loxP-eGFP (R/G) reporter  and an additional lentiviral vector carrying the expression of Cre recombinase under the control of the albumin promoter (ALB-Cre, Figure 3(a)). R/G treatment resulted in DsRed2, but not eGFP, expression in 84.1 ± 3.1% of cells. The albumin promoter activates the expression of Cre recombinase only in albumin-positive cells. Cre recombinase cleaves the “floxed” DsRed2, allowing the constitutive expression of eGFP under the same CMV promoter (Figure 3). The dual lentivirus system exhibited a high level of specificity; no eGFP-positive cells were detected in non-liver cells, such as pancreatic βTC1 cells (Figures 3(e), 3(f), and 3(g)), and Cre recombinase expression colocalized with albumin (Figures 3(h), 3(i), 3(j), and 3(k)). Because most adult human liver cells express albumin (88 ± 6%, Figure 2(a)), we expected that the majority of cells infected by both lentiviruses would have activated Cre recombinase and become eGFP-positive. The efficiency of infection with a single lentivirus was ~85%, and double infection resulted in 72% eGFP-positive cells, using CMV-Cre as control. Adult human liver cells infected with the two-lentivirus system (R/G and ALB-Cre) resulted in 69.4 ± 7.6% eGFP-positive cells within ten days of infection, with few cells expressing both eGFP and DsRed2 protein (Figure 3(d)). Colabeling with eGFP and DsRed2 likely reflects the activity of the albumin promoter and the relatively long half-life of the DsRed2 protein ( days), such that the DsRed2 protein can be detected even 1-2 weeks after the DsRed2 gene is no longer expressed . Only 9.3 ± 5.4% of the cells remained irreversibly positive for DsRed2. These cells, in part, represent an incapability to activate albumin expression (about 2%-3%) and/or cells infected only with the reporter vector CMV-loxP-DsRed2-loxP-eGFP but not by the ALB- Cre lentivirus vector.
3.5. Characterization of Cells Irreversibly Tagged for Albumin Expression by eGFP
eGFP-labeled liver cells were separated from DsRed2-positive cells by FACS-Sorter and cultured separately for several passages (Figures 4(a), 4(b), 4(c), 4(e), and 4(f)). Two weeks after sorting (3 passages), less than 3% of DsRed2-positive cells were detected among the eGFP-positive population, the vast majority of which were colabeled by eGFP (data not shown), suggesting a highly purified culture of albumin-positive, eGFP-labeled cells.
The eGFP and DsRed2 populations exhibited distinct hepatic marker expression. In addition to increased expression of the albumin gene in eGFP-positive cells (Figure 4(g)), additional adult hepatic markers, such as ADH1b, GLUL, and the transcription factor CEBPβ, were expressed to higher levels compared to the DsRed2-positive cells (Figure 4(g)). However, the expression level of the hepatic genes in eGFP-positive cells was lower than that of cells at passage 2–4 (Figure 1(b)), further suggesting an ongoing dedifferentiation process which occurs in culture with time. The expression of immature or progenitor markers, such as AFP and CK19, was similarly detected in both groups (data not shown). In contrary, the DsRed2-positive cells were enriched for αSMA, desmin, and GFAP expression compared to the eGFP-positive cells (Figure 4(h)). αSMA, desmin, and GFAP are typically considered to be hepatic stellate cell markers . Although stellate cells are considered mesenchymal cells , they do not usually express the mesenchymal marker CD90. The fact that DsRed2 cells also expressed αSMA, desmin, and GFAP but low levels of CD90 (Figure 4(i)) suggests that indeed, the DsRed2 population of cells may include the hepatic stellate cell population. Flow cytometry and immunofluorescence confirmed that each of the isolated eGFP-positive cells expressed albumin, CD105, and CD90 at higher levels than DsRed2-positive cells (Figures 4(j) and 4(k) and data not shown).
3.6. Ectopic PDX-1 Expression Induces Cellular Reprogramming
Next, we sought to analyze which of the two liver cell populations preferentially support PDX-1-induced reprogramming, manifested as induced insulin production. eGFP-positive cells and DsRed2-positive cells were separately treated with Ad-PDX-1 and supplemented with soluble factors as previously described . Ectopic PDX-1 expression resulted in a significant decrease in albumin gene expression (data not shown) . However, ectopic PDX-1 expression did not affect the expression of CD105 and CD90 in the separate cultures (data not shown). Ectopic PDX-1 expression in eGFP positive cells activated the expression of pancreatic hormones gene expression (INS, GCG, and SST; Figure 5(a)), the expression of genes involved in β-cell glucose sensing (GLUT-2, GK), and prohormone processing (PC2) (Figure 5(b)). Only the expression of somatostatin was significantly activated in DsRed2 positive cells. Moreover, PDX-1 treatment resulted in insulin production, which mainly colocalized with eGFP; 17.6 ± 3.5% of eGFP-positive cells coexpressed insulin (Figures 5(c)–5(h)). In contrast, only 3.35 ± 2.1% of DsRed2-positive cells was also positive for insulin in response to a similar reprogramming protocol (data not shown). Because about 28% of the DsRed2-positive cells could have been positive for albumin but not eGFP, the actual percentage of insulin-positive cells generated in albumin-negative human liver cells is even lower than 3.35 ± 2.1%. Taken together, these data suggest that albumin-positive cells represent the vast majority of liver cells that undergo reprogramming along the pancreatic lineage.
Using a genetic lineage-tracing approach, we demonstrate for the first time that the insulin-producing cells induced by ectopic expression of the pancreatic transcription factor PDX-1 in human liver cells mainly originate from albumin-positive cells. The proliferating adherent human liver cells express both adult liver and mesenchymal cell markers and possess a considerable level of developmental plasticity (Figures 1 and 2).
Most liver-derived cells in the primary culture express mesenchymal characteristics (Figure 2). The origin of these hepatic MSC-like cells is not clear; they could represent liver cells that underwent EMT, or the cells may represent a preexisting population of stem-like cells with self-replication capacity, which normally serve as hepatic progenitor cells. The precise combination of markers that characterize human hepatic progenitor cells is controversial ; thus, it is complicated to completely rule out the possibility that our culture conditions promoted the amplification of pre-existing human hepatic stem-like cells. However, the comprehensive characterization of the primary culture of the human liver-derived cells seems to favor the option that insulin-producing cells are generated in dedifferentiated liver cells that underwent an EMT process, meaning that such cells, most likely, do not exist in the intact organ. This conclusion is based on several lines of evidence. First, 88% of the cells in culture are not only positive for albumin, but the albumin-positive cells also express higher levels of other adult hepatic markers, which is not expected to occur in pluripotent stem-like cells. Second, EpCAM is agreed upon as being a hepatic progenitor marker and is not expressed in our human-derived cells. Third, the only cells in the intact adult liver with mesenchymal characteristics are stellate cells. However, stellate cell marker expression was low in general and occurred mainly in the albumin-negative population, which had lower reprogramming efficiency (Figure 4(h)). Taken together, these data may suggest that the cells populating the majority of human liver-derived primary culture are not residents of the intact organ that underwent preferential proliferation. On the other hand, our human liver-derived primary culture exhibits several EMT characteristics, including specific mesenchymal marker expression (Figures 1 and 2), decreased E-CAD associated with increased N-CAD expression (Figure 1(b)), and the activation of Snail and Slug expression, the zinc finger transcription factors known to control the EMT process (Figure 1(c)) [40, 46].
Epithelial to mesenchymal transition is a common process that epithelial cells undergo upon in vitro culture [47–49]. In vivo, EMT plays a key role in morphogenic changes during embryonic development, wound healing/tissue regeneration, and neoplasia [25, 26, 30]. Several groups have demonstrated that the process is associated with the downregulation of epithelial gene expression and activation of mesenchymal gene expression [47–49]. EMT induction in vitro has been suggested in cultured thyroid cells  and adult human islets upon entrance into the cell cycle . More recently, direct evidence of EMT in cultured adult primary β-cells was demonstrated using genetic lineage tracing . The capacity of adult parenchymal liver cells to give rise to insulin-producing cells is further strengthened by in vivo studies. Direct administration of PDX-1 in mice in vivo suggests that the insulin-producing cells are primarily generated in parenchymal cells close to the central veins [8, 11, 25]. Hepatic pericentral cells are suggested adult, terminally differentiated, while adult hepatic stem cells mainly reside in periportal areas of the liver and in the Canals of Hering . While these observations need to be directly analyzed by a lineage tracing approach, they suggest that the reprogramming process does not primarily take place in bona fide adult hepatic stem cells.
Despite the uniform morphology of the human liver-derived cells in vitro, the cells seem to maintain different phenotypes with regard to albumin and the expression of other adult hepatic markers, which may correlate with distinct reprogramming capacity. Using irreversible lineage tracing for albumin promoter activity, we present supporting evidence that insulin-positive cells induced by ectopic PDX-1 expression are preferentially generated in cells that are originally albumin-positive (Figure 5). In a recent paper, Dan et al.  isolated human hepatic progenitor cells that carry the capacity to differentiate along multiple hepatic lineages, including mesenchymal cells. However, these cells did not express albumin. The colocalization of albumin expression with mesenchymal markers suggests that the reprogramming process of liver to pancreas does not occur in such cells but in hepatic dedifferentiated cells , which undergone an EMT process.
Because we also detected a small number of insulin-positive cells among the DsRed2-positive cells, we cannot rule out the possibility that nonalbumin-positive cells present in our culture underwent reprogramming and contributed to the insulin-producing cell population but with lower reprogramming efficiency.
The fact that the special mesenchymal cells coexpressing albumin do not induce tumors in immune-deficient rodents conveys a substantial safety advantage over using other progenitor cells in tissue engineering approaches [52, 53]. By contrast, other mesenchymal cells derived from bone marrow have been documented in numerous studies to carry a tumorigenic potential under similar conditions [41–43].
The data generated in this study provide a better understanding of the nature of primary human liver cell culture, which is capable of undergoing pancreatic transcription factor-induced reprogramming. Further dissection of subpopulations of cells within the liver-derived, albumin-positive mesenchymal cells will allow us to identify the specific characteristics of liver cells, which are predisposed to reprogramming to allow a substantial increase in the efficiency of the reprogramming process along the pancreatic lineage.
5. Conclusion and Summary
The present study suggests that the insulin-producing cells induced by ectopic expression of the pancreatic transcription factor PDX-1 in human liver cells mainly originate from albumin-positive cells. The proliferating adult human liver cells in culture acquire mesenchymal characteristics and a high level of cellular plasticity. However, while most liver cells in culture possess mesenchymal-like characteristics, insulin production is induced in albumin positive cells, which are enriched for adult hepatic markers expression. Identification and the characterization of cells prone to reprogramming along the β-cell lineage is expected to increase the reprogramming efficiency. It may allow developing controlled and reproducible reprogramming process, by overcoming the pronounced heterogeneity of cells in the primary cultures.
Reprogramming liver to pancreas offers the access to an abundant source of “self-tissue”. The approach obviates the shortage in tissue availability from cadaveric donors and the need for antirejection treatment, allowing the diabetic patient to be the donor of his own therapeutic tissue.
The authors thank Tamar Rubinek, Lilach Abramovitz, and Hagai Ligumsky for their guidance and assistance in performing the in vivo studies. They thank Dora Berman-Weinberg for her support of the in vitro studies and Kfir Molakandov, Keren Shternhall-Ron, and Vered Aviv for fruitful discussions, and Michael Walker and Shimon Efrat for critically reviewing the paper. This study was supported by Juvenile Diabetes Research Foundation no. 17-2006-1029. The authors declare no conflict of interest in their paper. This work was performed in partial fulfillment of the requirements for Ph.D. degree.
- S. Bonner-Weir and G. C. Weir, “New sources of pancreatic β-cells,” Nature Biotechnology, vol. 23, no. 7, pp. 857–861, 2005.
- I. Meivar-Levy and S. Ferber, “Regenerative medicine: using liver to generate pancreas for treating diabetes,” Israel Medical Association Journal, vol. 8, no. 6, pp. 430–434, 2006.
- C. A. Palma, R. Lindeman, and B. E. Tuch, “Blood into β-cells: an adult stem cells be used as a therapy for Type 1 diabetes?” Regenerative Medicine, vol. 3, no. 1, pp. 33–47, 2008.
- K. S. Zaret and M. Grompe, “Generation and regeneration of cells of the liver and pancreas,” Science, vol. 322, no. 5907, pp. 1490–1494, 2008.
- G. Deutsch, J. Jung, M. Zheng, J. Lóra, and K. S. Zaret, “A bipotential precursor population for pancreas and liver within the embryonic endoderm,” Development, vol. 128, no. 6, pp. 871–881, 2001.
- J. K. Reddy, S. Rao, A. V. Yeldandi, X. Tan, and R. S. Dwivedi, “Pancreatic hepatocytes. An in vivo model for cell lineage in pancreas of adult rat,” Digestive Diseases and Sciences, vol. 36, no. 4, pp. 502–509, 1991.
- M. D. Dabeva, S. G. Hwang, S. R. G. Vasa et al., “Differentiation of pancreatic epithelial progenitor cells into hepatocytes following transplantation into rat liver,” Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 14, pp. 7356–7361, 1997.
- I. Ber, K. Shternhall, S. Perl et al., “Functional, persistent, and extended liver to pancreas transdifferentiation,” Journal of Biological Chemistry, vol. 278, no. 34, pp. 31950–31957, 2003.
- L. Z. Cao, D. Q. Tang, M. E. Horb, S. W. Li, and L. J. Yang, “High glucose is necessary for complete maturation of Pdx1-VP16-expressing hepatic cells into functional insulin-producing cells,” Diabetes, vol. 53, no. 12, pp. 3168–3178, 2004.
- S. Ferber, A. Halkin, H. Cohen et al., “Pancreatic and duodenal homeobox gene 1 induces expression of insulin genes in liver and ameliorates streptozotocin-induced hyperglycemia,” Nature Medicine, vol. 6, no. 5, pp. 568–572, 2000.
- M. Koizumi, R. Doi, E. Toyoda et al., “Hepatic regeneration and enforced PDX-1 expression accelerate transdifferentiation in liver,” Surgery, vol. 136, no. 2, pp. 449–457, 2004.
- K. Shternhall-Ron, F. J. Quintana, S. Perl et al., “Ectopic PDX-1 expression in liver ameliorates type 1 diabetes,” Journal of Autoimmunity, vol. 28, no. 2-3, pp. 134–142, 2007.
- D. Q. Tang, S. Lu, Y. P. Sun et al., “Reprogramming liver-stem WB cells into functional insulin-producing cells by persistent expression of Pdx1- and Pdx1-VP16 mediated by lentiviral vectors,” Laboratory Investigation, vol. 86, no. 1, pp. 83–93, 2006.
- V. Aviv, I. Meivar-Levy, I. H. Rachmut, T. Rubinek, E. Mor, and S. Ferber, “Exendin-4 promotes liver cell proliferation and enhances PDX-1-induced liver to pancreas transdifferentiation,” Journal of Biological Chemistry, vol. 284, no. 48, pp. 33509–33520, 2009.
- S. Gefen-Halevi, I. H. Rachmut, K. Molakandov et al., “NKX6.1 promotes PDX-1-induced liver to pancreatic β-cells reprogramming,” Cellular Reprogramming, vol. 12, no. 6, pp. 655–664, 2010.
- T. Sapir, K. Shternhall, I. Meivar-Levy et al., “From the cover: cell-replacement therapy for diabetes: generating functional insulin-producing tissue from adult human liver cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 22, pp. 7964–7969, 2005.
- M. Zalzman, S. Gupta, R. K. Giri et al., “Reversal of hyperglycemia in mice by using human expandable insulin-producing cells differentiated from fetal liver progenitor cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 12, pp. 7253–7258, 2003.
- M. Zalzman, L. Anker-Kitai, and S. Efrat, “Differentiation of human liver-derived, insulin-producing cells toward the β-cell phenotype,” Diabetes, vol. 54, no. 9, pp. 2568–2575, 2005.
- W. C. Li, M. E. Horb, D. Tosh, and J. M. W. Slack, “In vitro transdifferentiation of hepatoma cells into functional pancreatic cells,” Mechanisms of Development, vol. 122, no. 6, pp. 835–847, 2005.
- I. M. Arias, J. L. Boyer, F. V. Chisari, N. Fausto, D. Schachter, and D. A. Shafritz, The Liver: Biology and Pathobiology, Williams & Wilkins, Philadelphia, Pa, USA, 4th edition, 2001.
- E. Gaudio, G. Carpino, V. Cardinale, A. Franchitto, P. Onori, and D. Alvaro, “New insights into liver stem cells,” Digestive and Liver Disease, vol. 41, no. 7, pp. 455–462, 2009.
- R. Turner, O. Lozoya, Y. Wang, et al., “Human hepatic stem cell and maturational liver lineage biology,” Hepatology, vol. 53, no. 3, pp. 1035–1045, 2011.
- H. Kojima, M. Fujimiya, K. Matsumura, T. Nakahara, M. Hara, and L. Chan, “Extrapancreatic insulin-producing cells in multiple organs in diabetes,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 8, pp. 2458–2463, 2004.
- H. Kojima, M. Fujimiya, K. Matsumura et al., “NeuroD-betacellulin gene therapy induces islet neogenesis in the liver and reverses diabetes in mice,” Nature Medicine, vol. 9, no. 5, pp. 596–603, 2003.
- J. Imai, H. Katagiri, T. Yamada et al., “Constitutively active PDX1 induced efficient insulin production in adult murine liver,” Biochemical and Biophysical Research Communications, vol. 326, no. 2, pp. 402–409, 2005.
- V. Yechoor, V. Liu, C. Espiritu et al., “Neurogenin3 is sufficient for transdetermination of hepatic progenitor cells into neo-islets in vivo but not transdifferentiation of hepatocytes,” Developmental Cell, vol. 16, no. 3, pp. 358–373, 2009.
- E. Schmelzer, E. Wauthier, and L. M. Reid, “The phenotypes of pluripotent human hepatic progenitors,” Stem Cells, vol. 24, no. 8, pp. 1852–1858, 2006.
- Y. Y. Dan, K. J. Riehle, C. Lazaro et al., “Isolation of multipotent progenitor cells from human fetal liver capable of differentiating into liver and mesenchymal lineages,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 26, pp. 9912–9917, 2006.
- J. Jozefczuk, H. Stachelscheid, L. Chavez et al., “Molecular characterization of cultured adult human liver progenitor cells,” Tissue Engineering—Part C, vol. 16, no. 5, pp. 821–834, 2010.
- I. Meivar-Levy, T. Sapir, S. Gefen-Halevi et al., “Pancreatic and duodenal homeobox gene 1 induces hepatic dedifferentiation by suppressing the expression of CCAAT/enhancer-binding protein β,” Hepatology, vol. 46, no. 3, pp. 898–905, 2007.
- H. M. Kim, S. B. Han, B. H. Hyun et al., “Functional human hepatocytes: isolation from small liver biopsy samples and primary cultivation with liver-specific functions,” Journal of Toxicological Sciences, vol. 20, no. 5, pp. 565–578, 1995.
- E. Thévenot, F. Côté, P. Colin et al., “Targeting conditional gene modification into the serotonin neurons of the dorsal raphe nucleus by viral delivery of the Cre recombinase,” Molecular and Cellular Neuroscience, vol. 24, no. 1, pp. 139–147, 2003.
- H. A. Russ, Y. Bar, P. Ravassard, and S. Efrat, “In vitro proliferation of cells derived from adult human β-cells revealed by cell-lineage tracing,” Diabetes, vol. 57, no. 6, pp. 1575–1583, 2008.
- I. Wolf, J. O'Kelly, N. Wakimoto et al., “Honokiol, a natural biphenyl, inhibits in vitro and in vivo growth of breast cancer through induction of apoptosis and cell cycle arrest,” International Journal of Oncology, vol. 30, no. 6, pp. 1529–1537, 2007.
- Y. Sakai, S. Yamagami, and K. Nakazawa, “Comparative analysis of gene expression in rat liver tissue and monolayer- and spheroid-cultured hepatocytes,” Cells Tissues Organs, vol. 191, no. 4, pp. 281–288, 2010.
- M. Inada, D. Benten, K. Cheng et al., “Stage-specific regulation of adhesion molecule expression segregates epithelial stem/progenitor cells in fetal and adult human livers,” Hepatology International, vol. 2, no. 1, pp. 50–62, 2008.
- M. E. Fomin, L. K. Tai, A. Barcena, and M. O. Muench, “Coexpression of CD14 and CD326 discriminate hepatic precursors in the human fetal liver,” Stem Cells and Development, vol. 2010, p. 2, 2010.
- H. A. Russ, P. Ravassard, J. Kerr-Conte, F. Pattou, and S. Efrat, “Epithelial-mesenchymal transition in cells expanded in vitro from lineage-traced adult human pancreatic beta cells,” PLoS One, vol. 4, no. 7, Article ID e6417, 2009.
- W. Ding, H. You, H. Dang et al., “Epithelial-to-mesenchymal transition of murine liver tumor cells promotes invasion,” Hepatology, vol. 52, no. 3, pp. 945–953, 2010.
- M. Zeisberg and E. G. Neilson, “Biomarkers for epithelial-mesenchymal transitions,” Journal of Clinical Investigation, vol. 119, no. 6, pp. 1429–1437, 2009.
- M. Miura, Y. Miura, H. M. Padilla-Nash et al., “Accumulated chromosomal instability in murine bone marrow mesenchymal stem cells leads to malignant transformation,” Stem Cells, vol. 24, no. 4, pp. 1095–1103, 2006.
- N. Serakinci, P. Guldberg, J. S. Burns et al., “Adult human mesenchymal stem cell as a target for neoplastic transformation,” Oncogene, vol. 23, no. 29, pp. 5095–5098, 2004.
- J. Tolar, A. J. Nauta, M. J. Osborn et al., “Sarcoma derived from cultured mesenchymal stem cells,” Stem Cells, vol. 25, no. 2, pp. 371–379, 2007.
- S. L. Friedman, “Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver,” Physiological Reviews, vol. 88, no. 1, pp. 125–172, 2008.
- J. Dudas, T. Mansuroglu, D. Batusic, B. Saile, and G. Ramadori, “Thy-1 is an in vivo and in vitro marker of liver myofibroblasts,” Cell and Tissue Research, vol. 329, no. 3, pp. 503–514, 2007.
- R. Kalluri and R. A. Weinberg, “The basics of epithelial-mesenchymal transition,” Journal of Clinical Investigation, vol. 119, no. 6, pp. 1420–1428, 2009.
- S. S. Choi and A. M. Diehl, “Epithelial-to-mesenchymal transitions in the liver,” Hepatology, vol. 50, no. 6, pp. 2007–2013, 2009.
- A. Kaimori, J. Potter, J. Y. Kaimori, C. Wang, E. Mezey, and A. Koteish, “Transforming growth factor-β1 induces an epithelial-to-mesenchymal transition state in mouse hepatocytes in vitro,” Journal of Biological Chemistry, vol. 282, no. 30, pp. 22089–22101, 2007.
- M. Zeisberg, C. Yang, M. Martino et al., “Fibroblasts derive from hepatocytes in liver fibrosis via epithelial to mesenchymal transition,” Journal of Biological Chemistry, vol. 282, no. 32, pp. 23337–23347, 2007.
- L. Ulianich, C. Garbi, A. S. Treglia et al., “ER stress is associated with dedifferentiation and an epithelial-to-mesenchymal transition-like phenotype in PC Cl3 thyroid cells,” Journal of Cell Science, vol. 121, no. 4, pp. 477–486, 2008.
- M. C. Gershengorn, A. A. Hardikar, C. Wei, E. Ceras-Raaka, B. Marcus-Samuels, and B. M. Raaka, “Epithelial-to-mesenchymal transition generates proliferative human islet precursor cells,” Science, vol. 306, no. 5705, pp. 2261–2264, 2004.
- E. E. Baetge, “Production of beta-cells from human embryonic stem cells,” Diabetes, Obesity and Metabolism, vol. 10, 4, pp. 186–194, 2008.
- D. Zhang, W. Jiang, M. Liu et al., “Highly efficient differentiation of human ES cells and iPS cells into mature pancreatic insulin-producing cells,” Cell Research, vol. 19, no. 4, pp. 429–438, 2009.